The 0.3% foam formulation of roflumilast was previously approved for the treatment of seborrheic dermatitis in adults and ...

Topical roflumilast 0.3% cream has been approved by the FDA to treat plaque psoriasis in patients 12 years and older since ...

Zoryve foam, 0.3% is a once-daily topical treatment for plaque psoriasis on the body and scalp. The Food and Drug Administration (FDA) has approved Zoryve ® (roflumilast) topical foam ...

The FDA approved a supplemental new drug application for roflumilast topical foam 0.3% for the treatment of plaque psoriasis ... group achieved Scalp Itch-Numeric Rating Scale success, defined ...

ZORYVE foam is a once-daily, steroid-free topical and is now widely available as a treatment for plaque psoriasis ... from baseline in Scalp Itch-Numeric Rating Scale (SI-NRS).

ZORYVE foam is a once-daily, steroid-free topical and is now widely available as a treatment for plaque psoriasis. Nearly 9 million ... by a ≥ 4-point change from baseline in Scalp Itch-Numeric Rating ...

Icotrokinra led to high rates of skin clearance in patients with scalp and genital psoriasis, according to results from the ICONIC-TOTAL study.

Accropeutics’ oral, selective TYK2/JAK1 inhibitor AC-201 has met the primary and key secondary endpoints in a Phase II ...

How does one live with psoriasis? From medication to nutrition (and beyond), Olivia Marks goes in search of clear answers.

Just a few weeks after its approval in the UK, Bristol-Myers Squibb’s new oral psoriasis therapy Sotyktu ... score above the threshold of 10 on a 30-point scale. The higher the DLQI score ...